SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

Internet Computer (ICP) is attracting significant attention as investors react to its emerging role in sovereign cloud infrastructure and AI-native digital development. The community remains focused on long-term accumulation, with ongoing discussions centered on its potential to offer a decentralized alternative to traditional cloud providers through recent partnerships and the rollout of new network engines.

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

Investors are actively debating the viability of the TRUMP crypto token, with significant community division between those calling it a failed scam that has lost nearly all its value and those holding out for a potential short squeeze or political-driven rebound. Much of the discourse focuses on the token's massive decline from its peak, leading to heated accusations of financial manipulation and fraud directed at the Trump brand and its associates.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is seeing active debate among investors as they weigh potential institutional adoption catalysts against ongoing frustration with its long-term price performance relative to the broader crypto market. The community is heavily focused on the project's foundational role in RWA tokenization and oracle infrastructure, driving a mix of aggressive accumulation by long-term believers and skepticism from those weary of the recent trend of stagnation.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech shares are experiencing increased volatility as investors weigh the company's ambitious oncology pipeline transition against leadership departures and broader regulatory scrutiny facing the mRNA sector. While the community remains divided over the firm's long-term valuation and clinical execution, discussions are heavily focused on upcoming Phase 3 data readouts that will determine the company's ability to diversify beyond its COVID-19 revenue base.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor ($TAO) is seeing a surge in investor interest driven by a perceived shift toward censorship-resistant AI, as recent regulatory actions against centralized models have increased demand for decentralized infrastructure. The community is actively debating the project's long-term utility versus its volatility, with many users focused on staking to capture rewards while treating the asset as a core long-term hedge against centralized tech limitations.

Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF

Tradr 2X Long ASTS Daily ETF

The Tradr 2X Long ASTS Daily ETF ($ASTX) is experiencing intense community focus as traders debate the risks and rewards of leveraging the high volatility of the underlying satellite stock. Investors are actively discussing the impact of daily decay and extreme price swings, with many using the ETF to capitalize on rapid momentum shifts while others warn of the dangers of holding such leveraged products during market corrections.

Procter & Gamble Co. engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances. The Health Care segment includes oral care products like toothbrushes, toothpaste, and personal health care such as gastrointestinal, rapid diagnostics, respiratory, and vitamins, minerals, and supplements. The Fabric and Home care segment consists of fabric enhancers, laundry additives and detergents, and air, dish, and surface care. The Baby, Feminine and Family Care segment sells baby wipes, diapers, and pants, adult incontinence, feminine care, paper towels, tissues, and toilet paper. The company was founded by William Procter and James Gamble in 1837 and is headquartered in Cincinnati, OH.

Procter & Gamble Co.

Procter & Gamble is trending as investors weigh its defensive appeal against recent macro headwinds and softening consumer demand. Market participants are actively debating whether the stock's current consolidation phase offers a value opportunity or signals a longer-term rotation out of consumer staples.

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK Plc - ADR

Glaxosmithkline plc - ADR

GlaxoSmithKline is currently trending due to its recent $2.2 billion acquisition of RAPT Therapeutics, a strategic move designed to bolster its immunology and food allergy pipeline with the long-acting candidate ozureprubart. Community sentiment is mixed as investors weigh the potential for long-term pipeline expansion against the broader market volatility facing major pharmaceutical firms.

ProShares Trust II - ProShares Ultra Silver 2x Shares

ProShares Ultra Silver

ProShares Ultra Silver is experiencing extreme volatility as traders speculate on the impact of geopolitical conflicts, industrial demand, and potential market manipulation in the silver futures space. The community is deeply divided, with many debating the sustainability of the recent price swings while positioning for either a rapid recovery or further downside based on fluctuations in the dollar and oil.

TOSHI

TOSHI is trending as the community expresses strong conviction in its pivot from a meme-based asset to an AI-driven utility token with an upcoming burn mechanism. Holders remain active in accumulating the token, viewing current consolidation as a prime buying opportunity while they anticipate a significant breakout fueled by Base ecosystem momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?

Here is how Amarin (AMRN) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?

Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals PR Newswire NASHVILLE, Tenn., June 10, 2026 Amneal's Commitment Helps Support a Reliable Supply of Essential...

Amneal and Pfizer GLP-1 Deal: New Growth Lever?

AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.

Is Amneal a Buy Before Rytary Generic Erosion?

AMRX faces Rytary generic pressure in 2026, but growth in generics, injectables, biosimilars, and higher profitability targets could support its outlook.

What's Driving Amneal's 2026 Growth Outlook?

AMRX's 2026 outlook is driven by higher profit expectations, a steady launch cadence, and growth from complex generics, injectables, and specialty brands.

Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Amneal Stock Up on FDA Nod for Romidepsin Injection Solution

AMRX gains after FDA approval of ready-to-use romidepsin injection, with 180-day exclusivity and a potential boost to its injectables portfolio.

Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is it a Good Idea to Invest in Amneal Pharmaceuticals Stock Now?

AMRX is building momentum with growth across specialty drugs and biosimilars, supported by new launches and a diversified portfolio.

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

AMRXAmneal Pharmaceuticals Inc - Ordinary Shares - Class A

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AMRX News